SAFETY DATA SHEET



Hardtop HB Comp B

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Hardtop HB Comp B

Product code : 52702
Product description : Hardener.
Product type : Liquid.

Other means of identification

: Not available.

UFI : 6U80-E0NV-J002-Y065

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use in coatings - Industrial use
Use in coatings - Professional use

See Annex to the Safety data sheet for additional information in the Exposure Scenario(s).

1.3 Details of the supplier of the safety data sheet

Jotun Paints (Europe) Ltd.

Stather Road

P.O.Box 2021
Flixborough, Scunthorpe

3202 Sandefjord

Flixborough, Scunthorpe 3202 Sandefji North Lincolnshire Norway

DN15 8RR Tel: +47 33 45 70 00
England Fax: +47 33 45 72 42
E-mail: SDSJotun@jotun.no

Tel: +44 17 24 40 00 00 Fax: +44 17 24 40 01 00

1.4 Emergency telephone number

Contact NHS Direct; phone 0845 4647 or 111. Open 24/7.

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Acute Tox. 4, H332 Skin Sens. 1, H317 STOT SE 3, H335 STOT SE 3, H336

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms :





Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 1/21

SECTION 2: Hazards identification

Signal word

: Warning.

Hazard statements

H226 - Flammable liquid and vapour.

H317 - May cause an allergic skin reaction.

H332 - Harmful if inhaled.

H335 - May cause respiratory irritation. H336 - May cause drowsiness or dizziness.

Precautionary statements

General

: Not applicable.

Prevention

: P280 - Wear protective gloves.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

sources. No smoking.

P261 - Avoid breathing vapour.

Response

P304 + P312 - IF INHALED: Call a POISON CENTER or doctor if you feel unwell.

P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. : P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.

Storage Disposal

: P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

Hazardous ingredients

hexane, 1,6-diisocyanato-, homopolymer

n-butyl acetate

2-methoxy-1-methylethyl acetate

tosvl isocvanate

hexamethylene-di-isocyanate

Supplemental label

elements

: EUH204 - Contains isocyanates. May produce an allergic reaction.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

: As from August 24 2023 adequate training is required before industrial or professional use.

Special packaging requirements

Containers to be fitted with child-resistant

fastenings

: Not applicable.

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

Date of issue/Date of revision Date of previous issue : 12.08.2022 :01.07.2022 Version:1 2/21

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	Weight %	Regulation (EC) No. 1272/2008 [CLP]	Type
hexane, 1,6-diisocyanato-, homopolymer	REACH #: 01-2119488934-20 EC: 500-060-2 CAS: 28182-81-2	≥50 - ≤75	Acute Tox. 4, H332 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
2-methoxy-1-methylethyl acetate	CAS: 123-60-4 REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
xylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7 Index: 601-022-00-9	<10	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
ethylbenzene	REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4	≤3	Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
tosyl isocyanate	EC: 223-810-8 CAS: 4083-64-1 Index: 615-012-00-7	<1	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 STOT SE 3, H335 EUH014	[1] [2]
hexamethylene-di-isocyanate	REACH #: 01-2119457571-37 EC: 212-485-8 CAS: 822-06-0	≤0.3	Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 3/21

SECTION 4: First aid measures

4.1 Description of first aid measures

General : In all cases of doubt, or when symptoms persist, seek medical attention. Never give

anything by mouth to an unconscious person. If unconscious, place in recovery

position and seek medical advice.

Eye contact: Remove contact lenses, irrigate copiously with clean, fresh water, holding the

eyelids apart for at least 10 minutes and seek immediate medical advice.

Inhalation : Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is

irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by

trained personnel.

Skin contact : Remove contaminated clothing and shoes. Wash skin thoroughly with soap and

water or use recognised skin cleanser. Do NOT use solvents or thinners.

Ingestion : If swallowed, seek medical advice immediately and show the container or label.

Keep person warm and at rest. Do NOT induce vomiting.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training. If it

is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing

thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin. Ingestion may cause nausea, diarrhea and vomiting.

Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : Adverse symptoms may include the following:

respiratory tract irritation

coughing

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

Skin contact: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments: No specific treatment.

See toxicological information (Section 11)

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 4/21

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

: Recommended: alcohol-resistant foam, CO2, powders, water spray or mist.

Unsuitable extinguishing media

: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : Fire will produce dense black smoke. Exposure to decomposition products may cause a health hazard.

Hazardous combustion products

Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen, hydrogen cyanide, monomeric isocyanates.

5.3 Advice for firefighters

Special protective actions for fire-fighters

: Cool closed containers exposed to fire with water. Do not release runoff from fire to drains or watercourses.

Special protective equipment for fire-fighters : Appropriate breathing apparatus may be required.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: Exclude sources of ignition and ventilate the area. Avoid breathing vapour or mist. Refer to protective measures listed in sections 7 and 8.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Do not allow to enter drains or watercourses. If the product contaminates lakes, rivers, or sewers, inform the appropriate authorities in accordance with local regulations.

6.3 Methods and material for containment and cleaning up

: Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Place in a suitable container. The contaminated area should be cleaned immediately with a suitable decontaminant. One possible (flammable) decontaminant comprises (by volume): water (45 parts), ethanol or isopropyl alcohol (50 parts) and concentrated (d: 0,880) ammonia solution (5 parts). A non-flammable alternative is sodium carbonate (5 parts) and water (95 parts). Add the same decontaminant to the remnants and let stand for several days until no further reaction in an unsealed container. Once this stage is reached, close container and dispose of according to local regulations (see section 13).

6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information

Date of issue/Date of revision :01.07.2022 : 12.08.2022 Date of previous issue Version :1 5/21

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

Persons with a history of asthma, allergies or chronic or recurrent respiratory disease should not be employed in any process in which this product is used.

Examination of lung function should be carried out on a regular basis on persons spraying this mixture.

7.1 Precautions for safe handling

Prevent the creation of flammable or explosive concentrations of vapours in air and avoid vapour concentrations higher than the occupational exposure limits.

In addition, the product should only be used in areas from which all naked lights and other sources of ignition have been excluded. Electrical equipment should be protected to the appropriate standard.

Mixture may charge electrostatically: always use earthing leads when transferring from one container to another.

Operators should wear antistatic footwear and clothing and floors should be of the conducting type.

Care should be taken when re-opening partly-used containers. Precautions should be taken to minimise exposure to atmospheric humidity or water. CO₂ will be formed, which, in closed containers, could result in pressurisation. Keep away from heat, sparks and flame. No sparking tools should be used.

Avoid contact with skin and eyes. Avoid the inhalation of dust, particulates, spray or mist arising from the application of this mixture. Avoid inhalation of dust from sanding.

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed.

Put on appropriate personal protective equipment (see Section 8).

Never use pressure to empty. Container is not a pressure vessel.

Always keep in containers made from the same material as the original one.

Comply with the health and safety at work laws.

Do not allow to enter drains or watercourses.

Information on fire and explosion protection

Vapours are heavier than air and may spread along floors. Vapours may form explosive mixtures with air.

When operators, whether spraying or not, have to work inside the spray booth, ventilation is unlikely to be sufficient to control particulates and solvent vapour in all cases. In such circumstances they should wear a compressed air-fed respirator during the spraying process and until such time as the particulates and solvent vapour concentration has fallen below the exposure limits.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations.

Notes on joint storage

Keep away from: oxidising agents, strong alkalis, strong acids.

Additional information on storage conditions

Observe label precautions. Store in a dry, cool and well-ventilated area. Keep away from heat and direct sunlight. Keep container tightly closed.

Keep away from sources of ignition. No smoking. Prevent unauthorised access. Containers that have been opened must be carefully resealed and kept upright to prevent leakage.

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

SECTION 8: Exposure controls/personal protection

The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

8.1 Control parameters

Occupational exposure limits

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 6/21

SECTION 8: Exposure controls/personal protection

Product/ingredient name	Exposure limit values
hexane, 1,6-diisocyanato-, homopolymer	EH40/2005 WELs (United Kingdom (UK), 1/2020). Inhalation
	sensitiser.
	STEL: 0.07 mg/m³, (as -NCO) 15 minutes.
and the state of t	TWA: 0.02 mg/m³, (as -NCO) 8 hours.
n-butyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	STEL: 966 mg/m³ 15 minutes. STEL: 200 ppm 15 minutes.
	TWA: 724 mg/m³ 8 hours.
	TWA: 150 ppm 8 hours.
2-methoxy-1-methylethyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 548 mg/m³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 274 mg/m ³ 8 hours.
	TWA: 50 ppm 8 hours.
xylene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 441 mg/m³ 15 minutes.
	STEL: 100 ppm 15 minutes. TWA: 220 mg/m³ 8 hours.
	TWA: 220 mg/m² 6 hours. TWA: 50 ppm 8 hours.
ethylbenzene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
etryberizerie	through skin.
	STEL: 552 mg/m³ 15 minutes.
	STEL: 125 ppm 15 minutes.
	TWA: 100 ppm 8 hours.
	TWA: 441 mg/m ³ 8 hours.
tosyl isocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Inhalation
	sensitiser.
	STEL: 0.07 mg/m³, (as -NCO) 15 minutes.
	TWA: 0.02 mg/m³, (as -NCO) 8 hours.
hexamethylene-di-isocyanate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Inhalation
	sensitiser. Notes: as NCO
	STEL: 0.07 mg/m³, (as -NCO) 15 minutes.
	TWA: 0.02 mg/m³, (as -NCO) 8 hours.

procedures

Recommended monitoring: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Date of issue/Date of revision : 12.08.2022 :01.07.2022 Date of previous issue Version :1 7/21

SECTION 8: Exposure controls/personal protection

Product/ingredient name	Exposure	Value	Population	Effects
hexane, 1,6-diisocyanato-, homopolymer	Long term Inhalation	0.5 mg/m³	Workers	Local
	Short term	1 mg/m³	Workers	Local
n-butyl acetate	Inhalation Short term	960 mg/m³	Workers	Systemic
	Inhalation Short term	960 mg/m³	Workers	Local
	Inhalation Long term	480 mg/m³	Workers	Systemic
	Inhalation Long term	480 mg/m³	Workers	Local
	Inhalation Short term Inhalation	859.7 mg/ m³	General population	Systemic
	Short term Inhalation	859.7 mg/ m³	[Consumers] General population	Local
	Long term Inhalation	102.34 mg/ m³	[Consumers] General population	Systemic
	Long term	102.34 mg/	[Consumers] General	Local
	Inhalation Long term Dermal	m³ 3.4 mg/kg	population [Consumers] General	Systemic
	Long term Dermal	bw/day 7 mg/kg	population Workers	Systemic
	Long term	bw/day 12 mg/m³	General	Systemic
	Inhalation Long term Inhalation	48 mg/m³	population Workers	Systemic
	Short term Oral	2 mg/kg bw/day	General population	Systemic
	Long term Oral	2 mg/kg bw/day	General population	Systemic
	Short term Dermal	6 mg/kg bw/day	General population	Systemic
	Short term Dermal	11 mg/kg bw/day	Workers	Systemic
	Long term Inhalation	35.7 mg/m³	General population	Local
	Short term Inhalation	300 mg/m ³	General population	Local
	Short term Inhalation	300 mg/m ³	General population	Systemic
	Long term Inhalation	300 mg/m³	Workers	Local
	Short term Inhalation	600 mg/m ³	Workers	Local
2 mothovy 1 mothylathyl acetata	Short term Inhalation	600 mg/m ³	Workers	Systemic
2-methoxy-1-methylethyl acetate	Long term Dermal Long term	153.5 mg/ kg bw/day 275 mg/m³	Workers Workers	Systemic Systemic
	Inhalation Long term Dermal	54.8 mg/	General	Systemic
	Lamata	kg bw/day	population [Consumers]	Circles-!-
	Long term	33 mg/m³	General	Systemic

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 8/21

SECTION 8: Exposure controls/personal protection

Long term Oral Long term Inhalation Long term Inhal	<u> </u>	<u> </u>	-		
Long term Oral Inhalation Long term Inhalation Inhalation Short term Inhalation Short term Inhalation		Inhalation		population	
Long term Oral Inhalation Long term Inhalation Inhalation Short term Inhalation Short term Inhalation					
Long term Inhalation Long term		Long term Oral	1 67 mg/		Systemic
Long term Inhalation Long term Oral Long term Dermal Inhalation Long term Dermal Long term Dermal Long term Dermal Inhalation Long term Dermal Long term		Long torm oran	•		Systemis
Long term Inhalation Long term Dermal Morkers Systemic Deputation Seneral population Ceneral population Ceneral population Systemic Devices of Morkers Devices			ky bw/day		
Inhalation Long term Inhalation Long term Dermal Long term Dermal Long term Dermal Long term Dermal Short term Inhalation Long term Dermal Long term Oral Long term Dermal Short term Inhalation Long term Dermal		1.			
Long term Inhalation Long term Oral Long term Oral Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Long term Oral Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Long term Inhalation Long term Dermal Inhalation Short term Inhalation Long term Dermal Inhalation		Long term	33 mg/m³		Local
Long term Inhalation Long term Oral Inhalation Long term Oral Long term Undatation Long term Dermal Inhalation Long term Oral Long term Inhalation Long term Dermal Inhalation Lo		Inhalation		population	
Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Inhalat		Long term	33 mg/m ³		Systemic
Long term Oral byday Long term Inhalation Long term Dermal Inhalation Long term Dermal Varies Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Oral Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Inhalation Long term Inhal			00 mg/m		C you connie
Long term Inhalation Long term Dermal Systemic Devices Systemic Development of Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalatio			26//		Cyatamia
Long term Dermal Inhalation Long term Dermal Short term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Dermal Inhalation Short term Inhalation Short term Inhalation Long term Dermal Inhalation Short term Inhalation Short term Inhalation Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Inhalation Short term Inhalation Short term Inhalation Inhalation Inhalation Inhalation Inhalation Inng term Dermal Inhalation Inng term In		Long term Oral			Systemic
Inhalation Long term Dermal Short term Inhalation Long term Dermal Short term Long term Dermal Inhalation Long term Dermal Short term Long term Dermal Long ter					
Inhalation Long term Dermal Short term Inhalation Long term Dermal Short term Long term Dermal Inhalation Long term Dermal Short term Long term Dermal Long ter		Long term	275 mg/m ³	Workers	Systemic
Long term Dermal Systemic population workers Systemic population workers worke			J		
Short term Inhalation Long term Dermal Workers Systemic Demolation Long term Dermal Inhalation Long term Dermal In			320 ma/ka	Conoral	Systemic
Short term Inhalation Long term Oral Long term Oral Long term Inhalation Long term Dermal Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Inhalation Inhalation Inhalation Inhalation Long term Oral Long term Inhalation Long term Oral Long term Inhalation Long term Inhalation Long term Oral Long		Long term berman			Oysternic
Inhalation Long term Dermal Long term Dermal Long term Long term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term					
xylene Long term Dermal Long term Oral Long term Oral Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Inhalation Inhalation Inhalation Short term Inhalation Inhalation Long term Oral Long term Oral Long term Oral Long term Inhalation Long term Inhalation Long term Oral Long term		Short term	550 mg/m³	Workers	Local
xylene Long term Oral Long term Inhalation Long term Dermal Inhalation Long term Dermal Long term Dermal Long term Dermal Short term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Lon		Inhalation			
xylene Long term Oral Long term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Unithalation Short term Inhalation Short term Inhalation Inhalation Inhalation Short term Inhalation Inhalation Inhalation Inhalation Inhalation Short term Inhalation In		Long term Dermal	796 ma/ka	Workers	Systemic
xylene Long term Oral Long term 1.6 mg/kg bw/day 14.8 mg/m² 14.		Long torm Bornia		Workers	Systemis
Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Short term 260 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Short term 215 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Inhalation Inhalation Short term 260 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Inhala	and an a		•	0	0
Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Long term Dermal Inhalation Long term Dermal Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Long term Dermal Inhalation Short term Inhalation Short term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Short term Inhalation Long term Userm Inhalation Long term Userm Inhalation Long term Userm	xyiene	Long term Oral			Systemic
Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Short term 289 mg/m³ Workers Systemic Morkers Systemic					
Inhalation Long term Dermal Inhalation Long term Dermal Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Oral Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Inhalation Long term Dermal Lon		Long term			Systemic
Long term Inhalation Long term Dermal Short term Inhalation Long term Dermal Inhalation L					
Inhalation Long term Dermal Long term Dermal Long term Dermal Long term Dermal Short term Inhalation Long term Dermal Inhalation Long term Inhalation Long term Dermal Inhalation Inhalation Inhala			77 m c/m 3		Cyptomic
Long term Dermal by which with the propulation workers by systemic by which and population and population and population between the population and population an			// ing/m ³	vvorkers	Systemic
bw/day 180 mg/kg bw/day 289 mg/m³ lnhalation Short term 289 mg/m³ lnhalation Long term 260 mg/m³ lnhalation Short term 260 mg/m³ lnhalation Long term Oral Long term 15 mg/m³ lnhalation Long term 293 mg/m² lnhalation Long term 442 mg/m³ lnhalation Long term 442 mg/m³ lnhalation Long term 442 mg/m³ lnhalation Long term 884 mg/m³ lnhalation Long term 0ral long term 0.46 mg/ kg bw/day Long term Dermal long term 0.8 mg/m³ lnhalation Long term 0.9 mg/m³ lnhalation Long term 0.9 mg/m³ lnhalation Long term Dermal long term Dermal long term Dermal long term 0.9 mg/m³ lnhalation Long term Dermal long term 0.9 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Long term Dermal long term Dermal long term Dermal long term 0.9 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Short term Short					
bw/day 180 mg/kg bw/day 289 mg/m³ lnhalation Short term 289 mg/m³ lnhalation Long term 260 mg/m³ lnhalation Short term 260 mg/m³ lnhalation Long term Oral Long term 15 mg/m³ lnhalation Long term 293 mg/m² lnhalation Long term 442 mg/m³ lnhalation Long term 442 mg/m³ lnhalation Long term 442 mg/m³ lnhalation Long term 884 mg/m³ lnhalation Long term 0ral long term 0.46 mg/ kg bw/day Long term Dermal long term 0.8 mg/m³ lnhalation Long term 0.9 mg/m³ lnhalation Long term 0.9 mg/m³ lnhalation Long term Dermal long term Dermal long term Dermal long term 0.9 mg/m³ lnhalation Long term Dermal long term 0.9 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Long term Dermal long term Dermal long term Dermal long term 0.9 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Short term Short		Long term Dermal	108 mg/kg	General	Systemic
Short term 289 mg/m³ lnhalation Short term 180 mg/kg bw/day 289 mg/m³ lnhalation Short term 289 mg/m³ lnhalation Long term 180 mg/m³ lnhalation Short term 260 mg/m³ lnhalation Short term 260 mg/m³ lnhalation Short term 260 mg/m³ lnhalation Long term 180 mg/kg bw/day 180 lnhalation Long term 180 mg/kg bw/day Short term 293 mg/m³ lnhalation Long term 180 mg/kg bw/day Short term 180 mg/kg bw/day Long term Dermal Short term 884 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Short term 180 mg/kg bw/day Long term Dermal Short term 884 mg/m³ lnhalation Short term 884 mg/m³ lnhalation Long term Dermal Long term Dermal Short term 884 mg/m³ lnhalation Long term Dermal Long term Dermal Short term 884 mg/m³ lnhalation Long term Dermal Long term Dermal Short term 884 mg/m³ lnhalation Long term Dermal Systemic Systemic Systemic Systemic Systemic Depulation General population General population General Systemic Systemic Systemic Depulation Systemic Depulation Systemic Systemic Depulation				population	
Short term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Inhalation Long term Inhalation Short term Inhalation Short term 260 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Short term 260 mg/m³ Inhalation Inha		Long term Dermal			Systemic
Short term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Short term 260 mg/m³ Inhalation Long term 221 mg/m³ Inhalation Long term 07al 1.6 mg/kg bw/day 293 mg/m³ Inhalation Long term 15 mg/m³ Inhalation Long term 293 mg/m³ Inhalation Long term 384 mg/m³ Workers Systemic Systemic Workers Systemic Workers Systemic Systemic Systemic Norkers Systemic Workers Systemic Systemic Norkers Systemic Systemic Norkers Systemic Systemic Norkers Systemic Systemic Norkers Systemic Syste		Long term berman		WOINGIS	Systemic
Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation					
Short term Inhalation Long term Inhalation Short term 260 mg/m³ Inhalation Long term 221 mg/m³ Inhalation Long term Oral Long term 15 mg/m³ Inhalation Long term 16 mg/m³ Inhalation Long term 17 mg/m³ Inhalation Long term 180 mg/kg bw/day Short term 293 mg/m³ Workers Systemic Dopulation Workers Systemic Systemic Dopulation Workers Systemic Dopulation Short term 293 mg/m³ Workers Systemic Dopulation Short term 293 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term Inhalation Long term Dormal Inhalation Long term Dormal Long term		Short term	289 mg/m³	Workers	Local
Short term Inhalation Long term Inhalation Short term 260 mg/m³ Inhalation Long term 221 mg/m³ Inhalation Long term Oral Long term 15 mg/m³ Inhalation Long term 16 mg/m³ Inhalation Long term 17 mg/m³ Inhalation Long term 180 mg/kg bw/day Short term 293 mg/m³ Workers Systemic Dopulation Workers Systemic Systemic Dopulation Workers Systemic Dopulation Short term 293 mg/m³ Workers Systemic Dopulation Short term 293 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term 884 mg/m³ Workers Systemic Dopulation Short term Inhalation Long term Dormal Inhalation Long term Dormal Long term		Inhalation			
Inhalation Long term Inhalation Short term Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Inha			289 ma/m ³	Workers	Systemic
Long term Inhalation Short term Inhalation I			200 mg/m	VVOIRCIS	Oysternic
Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Inh					l
Short term Inhalation Short term Inhalation Short term Inhalation Long term Inhalation Long term Oral Long term Inhalation Short term Inhalation Inhalation Inhalation Short term Inhalation In			65.3 mg/m ³		Local
Inhalation Short term Inhalation Long term Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Is mg/m³ Inhalation Long term Is mg/m³ Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Oral Inhalation Long term Dermal Inhalation Long term Oral Inhalation Inha		Inhalation		population	
Inhalation Short term Inhalation Long term Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Is mg/m³ Inhalation Long term Is mg/m³ Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Oral Inhalation Long term Dermal Inhalation Long term Oral Inhalation Inha		Short term	260 mg/m ³	General	Local
Short term Inhalation Long term Oral Inhalation Ethylbenzene Ethylbenzene Ethylbenzene Ethylbenzene Ethylbenzene Long term Oral Long term Oral Inhalation Long term Oral Long term Oral Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Oral Inhalation Long term Dermal Inhalation Long term Oral Inhalation Long term Dermal			_00g,		
Inhalation Long term Inhalation Long term Oral Long term Oral Long term Oral Long term Oral Long term Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Long term Inhalation Long term Dermal Inhalation Inhalati			260 ma/m³		Cuatamia
ethylbenzene Long term Inhalation Long term Oral Long term Oral Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Long term Oral Long term Dermal Long term Oral Long term Dermal Long term Oral Long term Dermal Dong term Dermal Long term Dermal Long term Dermal Dong term Dermal Do			260 mg/m²		Systemic
ethylbenzene Inhalation Long term Oral 1.6 mg/kg bw/day Long term 15 mg/m³ General population General population Systemic population Workers Systemic Workers Systemic Syst					
ethylbenzene Long term Oral Long term 1.6 mg/kg bw/day 15 mg/m³ 180 mg/kg bw/day 180 mg/kg bw/day		Long term	221 mg/m ³	Workers	Local
ethylbenzene Long term Oral Long term 1.6 mg/kg bw/day 15 mg/m³ 180 mg/kg bw/day 180 mg/kg bw/day		Inhalation	_		
Long term Inhalation Long term Oral Long term Inhalation Long term Ucong term Inhalation Long term Dermal Long term Dermal Inhalation Long term Ucong term	ethylhenzene		1.6 ma/ka	General	Systemic
Long term Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Undermus Inhalation In	Curyiberizerie	Long term Oral			Cysternic
Inhalation Long term Inhalation Long term Dermal Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Oral Long term Oral Long term Dermal Long term Inhalation Long term Dermal Long term Inhalation Long term Dermal Long term Inhalation Long term Dermal Systemic Systemic Vorkers Systemic Vorkers Systemic Systemic Systemic Systemic Systemic Systemic Systemic		.			
Long term Inhalation Long term Dermal Short term 293 mg/m³ Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Local Workers Local Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Outlier Systemic Now Short term 1000 and 1000			15 mg/m³		Systemic
Long term Inhalation Long term Dermal Short term 293 mg/m³ Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Local Workers Local Workers Systemic Workers Systemic Workers Systemic Workers Systemic Workers Systemic Outlier Systemic Now Short term 1000 and 1000		Inhalation		population	
Inhalation Long term Dermal Short term Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Inhalation Inhalation Long term Oral Long term Oral Long term Dermal Inhalation Long term Dermal Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Inhalation Long term Derm		Long term	77 ma/m³		Systemic
Long term Dermal Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Long term Oral Inhalation Long term Oral Long term Oral Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Long term Dermal Long term Dermal Long term Inhalation Long term Inhalation Long term Inhalation Long term Inhalation Long term Dermal Inhalation Inhala					'
Short term bw/day 293 mg/m³ Workers Local Long term Long term 442 mg/m³ Workers Local Inhalation Short term 884 mg/m³ Workers Systemic Inhalation Long term Oral 0.46 mg/ kg bw/day Long term Dermal Long term 0.46 mg/ kg bw/day Dopulation Cong term 0.8 mg/m³ Dopulation Cong term Dermal Cong term Dermal Dopulation D			100 mailes	Morkora	Cyptomia
Short term Inhalation Long term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation I		Long term Dermal		vvorkers	Systemic
Inhalation Long term Inhalation Short term Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Inhalati					
Inhalation Long term Inhalation Short term Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Oral Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Long term Dermal Inhalation Inhalati		Short term	293 mg/m ³	Workers	Local
Long term Inhalation Short term Short term Inhalation I					
Inhalation Short term Inhalation Long term Oral Long term Dermal Long term			442 ma/m ³	Workers	Local
Short term Inhalation Long term Oral Long term Dermal Dermal Long term Dermal Dermal Systemic			772 mg/m	VVOINGIO	Local
Inhalation Long term Oral Long term Dermal Long term Dermal Long term Dermal Long term Dermal Long term Dermal Long term Dermal Long term Dermal Dermal Long term Dermal De					
tosyl isocyanate Long term Oral Long term Dermal Long term Dermal Long term Dermal Long term Dermal Long term Long term Long term Long term Long term Dermal Long term Dermal Long term Dermal			884 mg/m³	Workers	Systemic
tosyl isocyanate Long term Oral Long term Dermal Long term Dermal Long term Dermal Long term Dermal Long term Long term Long term Long term Long term Dermal Long term Dermal Long term Dermal		Inhalation			
Long term Dermal Long term Dermal Long term Long term Long term Long term Long term Long term Dermal Long term Dermal Dermal Long term Dermal Dermal Dermal Long term Dermal Long term Dermal Der	tosyl isocyanate		0.46 ma/	General	Systemic
Long term Dermal Long term Dermal Long term Long term Long term Long term O.46 mg/ kg bw/day O.8 mg/m³ General population General population O.92 mg/ Workers Systemic			•		- ,
Long term Kg bw/day population Systemic population Cong term Dermal Cong term Cong ter		Lama ta Daniel			Cumtare:
Long term 0.8 mg/m³ General Systemic population Long term Dermal 0.92 mg/ Workers Systemic S		Long term Dermal			Systemic
Long term 0.8 mg/m³ General Systemic population Long term Dermal 0.92 mg/ Workers Systemic S			kg bw/day	population	
Inhalation Long term Dermal 0.92 mg/ Population Workers Systemic		Long term			Systemic
Long term Dermal 0.92 mg/ Workers Systemic			,		'
			0.02 mg/		Systemic
		Long term Dermal	U.82 IIIg/	MACIVEIS	Systemic
to of increa/Data of revision 12.09.2022 Data of previous increase 101.07.2022 Version 11.09.2022	l .	<u> </u>	1	I	<u> </u>

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 9/21

SECTION 8: Exposure controls/personal protection

		kg bw/day		
	Long term	3.24 mg/m ³	Workers	Systemic
	Inhalation			
hexamethylene-di-isocyanate	Short term	0.07 mg/m ³	Workers	Systemic
	Inhalation			
	Short term	0.07 mg/m ³	Workers	Local
	Inhalation			
	Long term	0.035 mg/	Workers	Systemic
	Inhalation	m³		
	Long term	0.035 mg/	Workers	Local
	Inhalation	m³		
	Long term	0.035 mg/	Workers	Local
	Inhalation	m³		
	Short term	0.07 mg/m ³	Workers	Local
	Inhalation			

PNECs

Product/ingredient name	Compartment Detail	Value	Method Detail
n-butyl acetate	Fresh water	0.18 mg/l	-
•	Marine	0.018 mg/l	-
	Sewage Treatment	35.6 mg/l	-
	Plant		
	Fresh water sediment	0.981 mg/kg dwt	-
	Marine water sediment	0.0981 mg/kg dwt	-
	Soil	0.0903 mg/kg dwt	_
2-methoxy-1-methylethyl acetate	Fresh water	0.635 mg/l	_
, , ,	Marine	0.0635 mg/l	-
	Sewage Treatment	100 mg/l	_
	Plant	J. J.	
	Fresh water sediment	3.29 mg/kg dwt	_
	Marine water sediment	0.329 mg/kg dwt	_
	Soil	0.29 mg/kg dwt	_
xylene	Fresh water	0.327 mg/l	_
	Marine	0.327 mg/l	_
	Sewage Treatment	6.58 mg/l	_
	Plant	0.00 mg/.	
	Fresh water sediment	12.46 mg/kg dwt	_
	Marine water sediment	12.46 mg/kg dwt	_
	Soil	2.31 mg/kg dwt	_
ethylbenzene	Fresh water	0.1 mg/l	_
54.1y.1551.1251.12	Marine	0.01 mg/l	_
	Sewage Treatment	9.6 mg/l	_
	Plant	o.o.mg/.	
	Fresh water sediment	13.7 mg/kg dwt	_
	Soil	2.68 mg/kg dwt	_
	Secondary Poisoning	20 mg/kg	_
hexamethylene-di-isocyanate	Fresh water	0.0774 mg/l	_
novamentylene-al-1900yanate	Marine	0.00774 mg/l	
	Sewage Treatment	8.42 mg/l	
	Plant	0.72 IIIg/I	=
	Fresh water sediment	0.01334 mg/kg	
	Tresti water sedililelit	dwt	=
	Marine water sediment	0.001334 mg/kg	
	water sediment	dwt	-
	Soil	0.0026 mg/kg dwt	
	JUII	U.UUZU IIIg/kg dwl	⁻

8.2 Exposure controls

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 10/21

SECTION 8: Exposure controls/personal protection

Persons with a history of asthma, allergies, chronic or recurrent respiratory disease should not be exposed to any process in which this product is used.

Examination of lung function should be carried out on a regular basis on persons spraying this mixture.

Appropriate engineering controls

Provide adequate ventilation. Where reasonably practicable, this should be achieved by the use of local exhaust ventilation and good general extraction. Air-fed protective respiratory equipment must be worn by the spray operator, even when good ventilation is provided. In other operations, if local exhaust ventilation and good general extraction are not sufficient to maintain concentrations of particulates and solvent vapours below the OEL, suitable respiratory protection must be worn. (See Occupational exposure controls.)

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying to EN 166 should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

Skin protection Gloves

: There is no one glove material or combination of materials that will give unlimited resistance to any individual or combination of chemicals.

The breakthrough time must be greater than the end use time of the product. The instructions and information provided by the glove manufacturer on use, storage, maintenance and replacement must be followed.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

Always ensure that gloves are free from defects and that they are stored and used correctly.

The performance or effectiveness of the glove may be reduced by physical/chemical damage and poor maintenance.

Barrier creams may help to protect the exposed areas of the skin but should not be applied once exposure has occurred.

Wear suitable gloves tested to EN374.

Not recommended, gloves(breakthrough time) < 1 hour: PE, neoprene May be used, gloves(breakthrough time) 4 - 8 hours: Viton®, nitrile rubber, butyl rubber, PVC

Recommended, gloves(breakthrough time) > 8 hours: 4H, Teflon, polyvinyl alcohol (PVA)

For right choice of glove materials, with focus on chemical resistance and time of penetration, seek advice by the supplier of chemical resistant gloves.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

Body protection

: Personnel should wear antistatic clothing made of natural fibres or of hightemperature-resistant synthetic fibres.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Self-contained respiratory equipment must be worn by spray operator, even when good ventilation is provided. By other operations than spraying, in well ventilated areas, air-fed respirators could be replaced by a combination charcoal filter and particulate filter mask.

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 11/21

SECTION 8: Exposure controls/personal protection

Environmental exposure

: Do not allow to enter drains or watercourses.

controls

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid. Colour Colourless. Odour : Characteristic. Odour threshold Not applicable. pН : Not applicable. Melting point/freezing point : Not applicable.

Initial boiling point and

boiling range

: 127 to 145°C (260.6 to 293°F)

: Closed cup: 34°C Flash point

Highest known value: 1 (n-butyl acetate) Weighted average: 0.73compared with **Evaporation rate**

butyl acetate

Flammability (solid, gas) : Not applicable. Upper/lower flammability or : 0.8 - 7.6%

explosive limits

: Highest known value: 1.5 kPa (11.3 mm Hg) (at 20°C) (n-butyl acetate). Vapour pressure

Weighted average: 0.37 kPa (2.78 mm Hg) (at 20°C)

Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Vapour density

Weighted average: 4.09 (Air = 1)

: 1.04 g/cm³ Density

Solubility(ies) : Insoluble in the following materials: cold water and hot water.

Partition coefficient: n-octanol/ : Not available.

water

Auto-ignition temperature : Lowest known value: 333°C (631.4°F) (2-methoxy-1-methylethyl acetate).

Decomposition temperature Not available.

: Kinematic (40°C): >20.5 mm²/s (>20.5 cSt) **Viscosity**

 Not available. **Explosive properties** : Not available. Oxidising properties

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity 10.2 Chemical stability

10.3 Possibility of hazardous reactions : The product reacts slowly with water, resulting in the production of carbon dioxide.

: Stable under recommended storage and handling conditions (see Section 7).

: In closed containers, pressure build-up could result in distortion, expansion and, in extreme cases, bursting of the container.

10.4 Conditions to avoid

: In a fire, hazardous decomposition products may be produced.

10.5 Incompatible materials

: Keep away from: oxidising agents, strong alkalis, strong acids, amines, alcohols,

water. Uncontrolled exothermic reactions occur with amines and alcohols.

10.6 Hazardous decomposition products : Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen, hydrogen cyanide, monomeric isocyanates.

Thermal decomposition (>200°C) may liberate anhydrides and relatively low concentrations of isocyanates.

Date of issue/Date of revision : 12.08.2022 :01.07.2022 : 1 12/21 Date of previous issue Version

SECTION 11: Toxicological information

11.1 Information on toxicological effects

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin. Ingestion may cause nausea, diarrhea and vomiting.

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
n-butyl acetate	LC50 Inhalation Vapour	Rat	>21.1 mg/l	4 hours
-	LD50 Dermal	Rabbit	>17600 mg/kg	-
	LD50 Oral	Rat	13100 mg/kg	-
2-methoxy-1-methylethyl	LD50 Dermal	Rabbit	>5 g/kg	-
acetate				
	LD50 Oral	Rat	8532 mg/kg	-
xylene	LC50 Inhalation Vapour	Rat	20 mg/l	4 hours
	LD50 Oral	Rat	4300 mg/kg	-
	TDLo Dermal	Rabbit	4300 mg/kg	-
ethylbenzene	LC50 Inhalation Vapour	Rat - Male	17.8 mg/l	4 hours
	LD50 Dermal	Rabbit	>5000 mg/kg	-
	LD50 Oral	Rat	3500 mg/kg	-
tosyl isocyanate	LD50 Oral	Rat	2234 mg/kg	-
hexamethylene-di-	LC50 Inhalation Dusts and	Rat	124 mg/m³	4 hours
isocyanate	mists			

Acute toxicity estimates

Route	ATE value
Inhalation (vapours)	13861.65 mg/kg 96.49 mg/l 2.37 mg/l

Irritation/Corrosion

Product/ingredient name	Exposure	Species	Score	Exposure	Observation
hexane, 1,6-diisocyanato-, homopolymer	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	500 mg	-
xylene	Eyes - Mild irritant	Rabbit	-	87 milligrams	-
	Skin - Mild irritant	Rat	-	8 hours 60 microliters	-
tosyl isocyanate	Eyes - Moderate irritant	Rabbit	-	100 microliters	-
	Skin - Mild irritant	Rabbit	-	24 hours 500 microliters	-
hexamethylene-di- isocyanate	Skin - Mild irritant	Mammal - species unspecified	-	-	-
	Eyes - Mild irritant	Mammal - species unspecified	-	-	-

Sensitisation

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 13/21

SECTION 11: Toxicological information

Product/ingredient name	Route of exposure	Species	Result
hexane, 1,6-diisocyanato-, homopolymer	skin	Mammal - species unspecified	Sensitising
hexamethylene-di- isocyanate	skin	Mammal - species unspecified	Sensitising

Mutagenicity

No known significant effects or critical hazards.

Carcinogenicity

No known significant effects or critical hazards.

Reproductive toxicity

Developmental effectsNo known significant effects or critical hazards.Fertility effectsNo known significant effects or critical hazards.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
hexane, 1,6-diisocyanato-, homopolymer	Category 3	-	Respiratory tract irritation
n-butyl acetate	Category 3	-	Narcotic effects
2-methoxy-1-methylethyl acetate	Category 3	-	Narcotic effects
xylene	Category 3	-	Respiratory tract irritation
tosyl isocyanate	Category 3	-	Respiratory tract irritation
hexamethylene-di-isocyanate	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
ethylbenzene	Category 2	-	hearing organs

Aspiration hazard

Product/ingredient name	Result	
xylene ethylbenzene	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1	

Other information : None identified.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself.

Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Product/ingredient name	Result	Species	Exposure
xylene	Acute LC50 8500 μg/l Marine water	Crustaceans - Palaemonetes pugio	48 hours
ethylbenzene	Acute LC50 13400 µg/l Fresh water Acute EC50 7700 µg/l Marine water Acute EC50 2.93 mg/l Acute LC50 4.2 mg/l	Fish - Pimephales promelas Algae - Skeletonema costatum Daphnia Fish	96 hours 96 hours 48 hours 96 hours

No known significant effects or critical hazards.

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 14/21

SECTION 12: Ecological information

12.2 Persistence and degradability

Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
xylene ethylbenzene	-	-	Readily Readily

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
hexane, 1,6-diisocyanato-, homopolymer	5.54	367.7	low
n-butyl acetate	2.3	-	low
2-methoxy-1-methylethyl acetate	1.2	-	low
xylene	3.12	8.1 to 25.9	low
ethylbenzene	3.6	-	low
hexamethylene-di- isocyanate	0.02	57.63	low

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

: Yes.

Disposal considerations

: Do not allow to enter drains or watercourses. Residues in empty containers should be neutralised with a decontaminant (see section 6).

Dispose of according to all federal, state and local applicable regulations.

If this product is mixed with other wastes, the original waste product code may no

longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 15/21

SECTION 13: Disposal considerations

Waste code	Waste designation
08 01 11*	Waste paint and varnish containing organic solvents or other dangerous substances

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Disposal considerations

: Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.

Result		European waste catalogue (EWC)
CEPE Guidelines	15 01 10*	packaging containing residues of or contaminated by hazardous substances

Special precautions

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	IATA
14.1 UN number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	Paint	Paint	Paint	Paint
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	III	III	III	III
14.5 Environmental hazards	No.	No.	No.	No.

Additional information

ADR/RID

: Hazard identification number 30

Tunnel code (D/E)

IMDG

Emergency schedules F-E, S-E

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not applicable.

Date of issue/Date of revision : 12.08.2022 :01.07.2022 Version:1 16/21 Date of previous issue

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles As from August 24 2023 adequate training is required before industrial or professional use.

Other EU regulations

VOC : The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the

product label and/or technical data sheet for further information.

VOC for Ready-for-Use

Mixture

: Not applicable.

Europe inventory : All components are listed or exempted.

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Seveso Directive

This product may add to the calculation for determining whether a site is within the scope of the Seveso Directive on major accident hazards.

National regulations

Industrial use

: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety

assessment

: Not applicable.

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 17/21

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and

: ATE = Acute Toxicity Estimate

acronyms

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Acute Tox. 4, H332	Calculation method
Skin Sens. 1, H317	Calculation method
STOT SE 3, H335	Calculation method
STOT SE 3, H336	Calculation method

Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.
H226	Flammable liquid and vapour.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H332	Harmful if inhaled.
H334	May cause allergy or asthma symptoms or breathing difficulties if
	inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H373	May cause damage to organs through prolonged or repeated
	exposure.
H412	Harmful to aquatic life with long lasting effects.
EUH014	Reacts violently with water.
EUH066	Repeated exposure may cause skin dryness or cracking.

Full text of classifications [CLP/GHS]

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Resp. Sens. 1	RESPIRATORY SENSITISATION - Category 1
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED
	EXPOSURE - Category 2
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE -
	Category 3

Date of printing : 12.08.2022 Date of issue/ Date of : 12.08.2022

revision

Date of previous issue : 01.07.2022

Version : 1

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 18/21

Conforms to Regulation (EC) No. 453/2010 (REACH), Annex II, as amended by Regulation (EU) No. 2015/830

Hardtop HB Comp B

SECTION 16: Other information

Notice to reader

The information in this document is given to the best of Jotun's knowledge, based on laboratory testing and practical experience. Jotun's products are considered as semi-finished goods and as such, products are often used under conditions beyond Jotun's control. Jotun cannot guarantee anything but the quality of the product itself. Minor product variations may be implemented in order to comply with local requirements. Jotun reserves the right to change the given data without further notice.

Users should always consult Jotun for specific guidance on the general suitability of this product for their needs and specific application practices.

If there is any inconsistency between different language issues of this document, the English (United Kingdom) version will prevail.

Date of issue/Date of revision : 12.08.2022 Date of previous issue : 01.07.2022 Version : 1 19/21



Exposure Scenario: Use in coatings - Industrial use

Sector of Use : Industrial use

Process Category : PROC05 PROC07 PROC08a PROC10

Environmental release category(ies) : ERC4

Covers the use in coatings (paints, inks, adhesives, etc) including exposures during use (including product transfer and preparation, application by brush, spray by hand or similar methods) and equipment cleaning.

Operational conditions and risk management measures

Control of worker exposure

Frequency and duration of use	: Covers daily exposures up to 8 hours
General - Operational conditions	: Assumes use at not more than 20°C above ambient temperature. Assumes a good basic standard of occupational hygiene is implemented
General - Risk management measures	: Wear chemical-resistant gloves (tested to EN374) in combination with specific activity training. Wear suitable coveralls to prevent exposure to the skin. Use suitable eye protection. See Section 8 for information on appropriate personal protective equipment.

Type of activity or process Risk management measures

Type of activity of process	Nisk management measures
Preparation of material for application	: Provide a good standard of controlled ventilation (10 to 15 air changes per hour).
Roller, spreader, flow application	: Provide extract ventilation to points where emissions occur.
Spraying - Manual	: Provide a good standard of controlled ventilation (10 to 15 air changes per hour). Wear a full-face respirator conforming to EN136 with Type A/P2 filter or better.

Control of environmental exposure

Control of Charlettal exposure	
Organisational measures to prevent/limit release from site	: Prevent environmental discharge consistent with regulatory requirements.
Conditions and measures related to external treatment of waste for disposal	: External treatment and disposal of waste should comply with applicable local and/or national regulations. See Section 13 for additional waste treatment information.
Conditions and measures related to external recovery of waste	 External recovery and recycling of waste should comply with applicable local and/or national regulations.

Additional information

The exposure scenario for the mixture is based on the following substances:

REACH #: 01-2119485796-17

Page: 20/21



Exposure Scenario: Use in coatings -Professional use

Sector of Use

: PROC05 PROC08a PROC10 PROC11 **Process Category**

Environmental release category(ies) : ERC8a ERC8d

Covers the use in coatings (paints, inks, adhesives, etc) including exposures during use (including product transfer and preparation, application by brush, spray by hand or similar methods) and equipment cleaning.

Operational conditions and risk management measures

Control of worker exposure

Frequency and duration of use	: Covers daily exposures up to 8 hours
General - Operational conditions	: Assumes use at not more than 20°C above ambient temperature. Assumes a good basic standard of occupational hygiene is implemented
General - Risk management measures	: Wear chemical-resistant gloves (tested to EN374) in combination with specific activity training. Wear suitable coveralls to prevent exposure to the skin. Use suitable eye protection. See Section 8 for information on appropriate personal protective equipment.

	suitable coveralls to prevent exposure to the skin. Use suitable eye protection. See Section 8 for information on appropriate personal protective equipment.
Type of activity or process	Risk management measures
Preparation of material for application - Indoor	: Provide a good standard of controlled ventilation (10 to 15 air changes per hour). Avoid carrying out activities involving exposure for more than 1 hour per day.
	Provide a good standard of controlled ventilation (10 to 15 air changes per hour). Wear a respirator conforming to EN140 with type A/P2 filter or better.
Preparation of material for application - Outdoor	: Ensure operation is undertaken outdoors. Avoid carrying out activities involving exposure for more than 1 hour per day. or
	Ensure operation is undertaken outdoors. Wear a respirator conforming to EN140 with type A/P2 filter or better.
Equipment cleaning and maintenance	: Drain down system prior to equipment break-in or maintenance. Avoid carrying out activities involving exposure for more than 4 hours per day.
Roller, spreader, flow application - Indoor	 Provide a good standard of controlled ventilation (10 to 15 air changes per hour). Avoid carrying out activities involving exposure for more than 4 hours per day.
	Provide a good standard of controlled ventilation (10 to 15 air changes per hour). Wear a respirator conforming to EN140 with type A/P2 filter or better.
Roller, spreader, flow application - Outdoor	: Ensure operation is undertaken outdoors. Wear a respirator conforming to EN140 with type A/P2 filter or better. Avoid carrying out activities involving exposure for more than 4 hours per day.
Spraying - Manual - Indoor	: Minimise exposure by partial enclosure of the operation or equipment and provide extract ventilation at openings. Wear a full-face respirator conforming to EN136 with Type A/P2 filter or better. Avoid carrying out activities involving exposure for more than 4 hours per day.

Control of environmental exposure

Control of Chivinghinichtal exposure		
Organisational measures to prevent/limit release from site	: Prevent environmental discharge consistent with regulatory requirements.	
Conditions and measures related to external treatment of waste for disposal	: External treatment and disposal of waste should comply with applicable local and/or national regulations. See Section 13 for additional waste treatment information.	
Conditions and measures related to external recovery of waste	 External recovery and recycling of waste should comply with applicable local and/or national regulations. 	

: Ensure operation is undertaken outdoors. Wear a full-face respirator conforming to EN136 with Type A/P2 filter or better. Avoid carrying out activities involving exposure for more than 4 hours per day.

Additional information

Spraying - Manual - Outdoor

The exposure scenario for the mixture is based on the following substances:

REACH #: 01-2119485796-17

Page: 21/21